Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have been given an average recommendation of “Moderate Buy” by the ten brokerages that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.6667.

A number of brokerages have recently commented on ALT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Friday, March 27th. Citizens Jmp dropped their target price on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price (down from $25.00) on shares of Altimmune in a report on Monday, May 18th. William Blair reiterated a “market perform” rating on shares of Altimmune in a report on Thursday, March 5th. Finally, Wall Street Zen cut Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th.

Insider Transactions at Altimmune

In other Altimmune news, CEO Jerome Benedict Durso acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average price of $3.54 per share, for a total transaction of $70,800.00. Following the acquisition, the chief executive officer directly owned 32,500 shares in the company, valued at $115,050. The trade was a 160.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Altimmune

A number of large investors have recently bought and sold shares of ALT. Two Sigma Investments LP boosted its holdings in Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after acquiring an additional 1,559,562 shares during the period. State Street Corp boosted its holdings in Altimmune by 42.2% during the 4th quarter. State Street Corp now owns 5,119,703 shares of the company’s stock valued at $18,482,000 after acquiring an additional 1,518,448 shares during the period. Vanguard Group Inc. boosted its holdings in Altimmune by 23.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after acquiring an additional 1,206,514 shares during the period. Nuveen LLC boosted its holdings in Altimmune by 514.9% during the 4th quarter. Nuveen LLC now owns 1,244,211 shares of the company’s stock valued at $4,492,000 after acquiring an additional 1,041,856 shares during the period. Finally, Marshall Wace LLP purchased a new position in Altimmune during the 4th quarter valued at $3,331,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

Shares of Altimmune stock opened at $2.93 on Friday. The stock has a market cap of $569.81 million, a price-to-earnings ratio of -3.15 and a beta of 0.18. The company has a debt-to-equity ratio of 0.12, a quick ratio of 29.56 and a current ratio of 29.56. The stock has a 50 day moving average price of $3.15 and a 200-day moving average price of $4.05. Altimmune has a one year low of $2.56 and a one year high of $7.73.

Altimmune (NASDAQ:ALT) last announced its earnings results on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. Equities analysts expect that Altimmune will post -0.69 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.